To date, the most developed one is Belzutifan, which has already been approved by the FDA for patients with VHL disease and is currently being investigated in different settings of ccRCC disease; however, other second-generation HIF2A inhibitors are already in clinical development. The gene discussed is EPAS1; the disease is nonpapillary renal cell carcinoma.